Cas:86060-96-0 Fmoc-Cys(Acm)-OPfp manufacturer & supplier

We serve Chemical Name:Fmoc-Cys(Acm)-OPfp CAS:86060-96-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Fmoc-Cys(Acm)-OPfp

Chemical Name:Fmoc-Cys(Acm)-OPfp
CAS.NO:86060-96-0
Synonyms:Fmoc-Cys(Acm)-OPfp;N-Fmoc-S-Acetamidomethyl-L-Cysteine Pentafluorophenyl Ester
Molecular Formula:C27H21F5N2O5S
Molecular Weight:580.52300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:742.4ºC at 760 mmHg
Density:1.436g/cm3
Index of Refraction:1.578
PSA:119.03000
Exact Mass:580.10900
LogP:5.80340

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Fmoc-Cys(Acm)-OPfp chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Fmoc-S-Acetamidomethyl-L-Cysteine Pentafluorophenyl Ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Fmoc-Cys(Acm)-OPfp Use and application,Fmoc-Cys(Acm)-OPfp technical grade,usp/ep/jp grade.


Related News: The mode of cooperation between domestic API companies and large international companies can lower the export threshold. Fmoc-Cys(Acm)-OPfp manufacturer The Company selected the top-performing clone for generation of the master engineered iPSC bank for GMP production of FT819. Fmoc-Cys(Acm)-OPfp supplier Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures. Fmoc-Cys(Acm)-OPfp vendor The Company selected the top-performing clone for generation of the master engineered iPSC bank for GMP production of FT819. Fmoc-Cys(Acm)-OPfp factory The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.